FDA Approves New Indication for Pfizer's Depo-SubQ Provera 104

The FDA has approved Pfizer's depo-subQ provera 104 (medroxyprogesterone acetate injectable suspension) for the management of pain associated with endometriosis, a condition that occurs in women of reproductive age when excess endometrial tissue of the uterus is present in other areas of the body, most commonly on the ovaries or fallopian tubes.

Depo-subQ provera 104 is a new formulation of Pfizer's Depo-Provera, which the FDA approved for use as a contraceptive in December 2004.